Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.French molecular diagnostic company Ipsogen has signed a licensing agreement with Arup Laboratories, a national clinical and anatomic pathology reference laboratory, to offer JAK2 molecular diagnostic testing in the US.
Subscribe to our email newsletter
According to the terms of the agreement, Ipsogen grants Arup non-exclusive rights, for the US territory, to offer a complete range of assays for the molecular classification and the screening of myeloproliferative neoplasms (MPN). Additional terms were not disclosed.
Vincent Fert, chairman and CEO of Ipsogen, said: “This agreement with Arup, reinforces the medical value of the JAK2 test as a diagnostic tool for MPN supported by the World Health Organization guidelines and affirms the strong intellectual property position of Ipsogen’s JAK2 patent portfolio.”